Geron(US:GERN) ZACKS·2025-11-05 14:26Core Insights - Geron reported a quarterly loss of $0.03 per share, matching the Zacks Consensus Estimate, and an improvement from a loss of $0.04 per share a year ago [1] - The company generated revenues of $47.23 million for the quarter ended September 2025, missing the Zacks Consensus Estimate by 10.03%, but showing growth from $28.27 million in the same quarter last year [2] - Geron shares have declined approximately 67.5% year-to-date, contrasting with a 15.1% gain in the S&P 500 [3] Financial Performance - The company has surpassed consensus EPS estimates two times over the last four quarters [1] - Geron has also topped consensus revenue estimates two times in the last four quarters [2] - The current consensus EPS estimate for the upcoming quarter is -$0.04 on revenues of $58.5 million, and for the current fiscal year, it is -$0.13 on revenues of $199.53 million [7] Market Outlook - The stock's immediate price movement will largely depend on management's commentary during the earnings call [3] - The estimate revisions trend for Geron was unfavorable prior to the earnings release, resulting in a Zacks Rank 4 (Sell) for the stock, indicating expected underperformance in the near future [6] - The Medical - Biomedical and Genetics industry is currently in the top 40% of Zacks industries, suggesting a favorable outlook compared to the bottom 50% [8]